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1. Introduction
The human face has an important role in a person’s identity, communication and self-confi‐
dence. Thus, any disfigurement or deformity of the face can causes both functional and so‐
cial isolation. Facial cosmetic surgery seeks to rejuvenate and restore facial volume loss,
static and dynamic rhytids and facial form from the effects of aging, facial muscle move‐
ments and gravity. The sudden explosion in recent years of non-surgical rejuvenative tech‐
niques is patient-driven. Addressing facial rhytids and undesirable skin changes has
required an in-patient stay and a significant period of recovery time. But today’s cosmetic
patients increasingly desire office-based procedures with minimal recovery time. They are
looking for maximal improvement with minimal risks, and cost that will provide them some
form of facial rejuvenation and at the same time allow them to get back to work or their so‐
cial lives as soon as possible. Minimal recovery procedures, offer patients significant esthetic
options with minimal or no recovery time and minimal risks. These procedures including
the use of injectable fillers, fat transfer, botulinum toxin injection and facial resurfacing tech‐
niques are among the most popular and widely performed office procedures. In this chap‐
ter, we discuss office-based facial cosmetic procedures, their indications and contra-
indications, benefits and risks and procedural methods.
2. Injectable fillers
Soft tissue augmentation with the various soft tissue filler materials is particularly per‐
formed on patients with minimal to moderate signs of facial aging and because of its non‐
surgical procedure and minimal downtime, is very popular.
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2.1. Background
Various materials for facial rejuvenation, such as wax, silicone and animal products have been
used. In 1893, Neuber used autologous fat transfer for soft tissue augmentation [1]. Paraffin and
vaseline were injected for soft tissue augmentation, just a few years later [2]. In 1940 liquid sili‐
cone was injected for cosmesis [3,4]. Bovine collagen injection became popular in 1980 [1].
2.2. Anatomy of the skin
Human skin has several layers. The most superficial layer which acts as a barrier is the epider‐
mis. The deeper layer to epidermis is the dermis and it consists of the papillary dermis and the
reticular dermis. The papillary dermis contains a web of primarily type 3 collagen that reaches
the epidermis. The reticular dermis is primarily made of type 1 collagen fibers [5]. Elastic fibers
are very low and they are responsible for skin resiliency. Ground substance is also a part of der‐
mis and is composed of hyaluronic acids, glycosaminoglycans and proteins and it fills the
spaces between other components of dermis [6]. Sub cutis which is seen under the dermis, con‐
sists of fat which is responsible for skin volume.The amount of skin collagen decreases with ag‐
ing, which affects primarily type 1 collagen fibers [5]. In addition to aging, exposure to tobacco
smoke and excessive sun can cause a decrease in collagen fiber contents by increasing collage‐
nase levels responsible for wrinkle formation by loss of skin elasticity and turgor [7].
2.3. Filler types
Injectable filler products are syringes containing filler agents. Their needle size is propor‐
tional to the filler viscosity; the higher the viscosity, the larger the needle lumen. The small‐
est appropriate needle size is used to minimize injection pain [8].High viscous agents are
generally used for deeper defects and lower viscous fillers are ideal for superficial defects
[1]. The depth of the injection is also important. For superficial defects, the needle tip enters
the skin very superficially, but for moderate defects, the level of entrance is mid to deep der‐
mis, and for deeper defects, the needle tip enters at the level of dermal-sub cutis junction.
After injection, gentle massage is required for evenness of the injected material.An ideal fill‐
er agent must meet criteria such as biocompatibity, and be non-antigenic, non-toxic, easy to
handle, long-lasting, inexpensive and reversible [8,9].Generally filler agents are categorized
into three groups, according to their duration: first, non-permanent fillers, which are short-
lasting fillers and they need repeated injections after their resorption. Second, semi-perma‐
nent fillers, which last longer but they will undergo some resorption as well. Third, the
permanent fillers which may be long lasting with only a single injection.
2.3.1. Non-permanent fillers
2.3.1.1. Collagen replacements
These agents are purified bovine or human collagen and before the advent of Hyaluronic
acid filler, was the ‘gold standard’ filler agents for many years. Bovine collagen was the first
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product approved by FDA for soft tissue augmentation [8,10].Because the possibility of al‐
lergy reaction, allergy testing was needed. It has been suggested to do the second skin test a
month later before augmentation [11,12].Several collagen replacements have been intro‐
duced: Zyderm, Zyplast, Cosmoderm and Cosmoplast (INAMED Aesthetics, Irvine, CA).
Zyderm and Zyplast are bovine collagen materials.Zyderm got FDA approval in 1981. Zy‐
plast was longer lasting and got FDA approval in 1985. [7]. All of these materials are eventu‐
ally degraded by inflammatory responses in 4- 5 months [8]. In 2003, Cosmoderm and
Cosmoplast were introduced into the market, which are human-derived collagen products.
They are derived from cultures of human fibroblast cells [8,13,14]. Because these products
are human-derived, there is no need for allergy testing and they are easier to use but their
longevity are less than bovine-collagen products [8].
2.3.1.2. Hyaluronic acid
Hyaluronic acid in a part of skin dermis and provides a scaffold for collagen development.
Aging decreases the amount of hyaluronic acid and this leads to decreasing of skin hydra‐
tion and elasticity and formation of rhytids and increased folds [15,16]. It increases the skin
hydration and turgor by binding to water molecules and helps to maintain the skin volume
and elasticity. It has a uniform structure among various species and this makes it a suitable
filler for injection, because there is no need for allergy testing. Its natural molecule is unsta‐
ble and will degrade in two days after injection [15]. Companies have cross-linked natural
hyaluronic acids to increase longevity and cross-linked materials are called hylans [8,17,18].
Hylans are highly viscous materials but their viscosity decreases by applying shear forces to
them, in this way their injection is easier [19,20].Hyaluronic acid fillers are injected intrader‐
mally, and if the result of injection is not desirable, hyaluronidase can be injected to degrade
the filler. Hyaluronic acid products are not combined with anesthetic agents, meaning anes‐
thetic local block injections may be necessary [19].During hyaluronic acid injections, the de‐
fect must be treated completely and no over-correction should be performed. The longevity
ranges between 6 to 9 months [17].The first hyaluronic acid product introduced into the
market was Restylane (Medicis Aesthetics, Inc., Scottsdale, Arizona) and received FDA ap‐
proval in 2003 [9,11]. It is a partially cross-linked hyaluronic acid and binds water strongly
and is derived from Streptococcus cultures [17] and is ideal for mid to deep dermal injec‐
tions [9,21]. The high degree of cross-linking is responsible for maintain its bulk and its sta‐
bility which makes it last up to 4 to 6 months depending on the injection site [21]. In contrast
to collagen materials which are simply degraded and lose volume, when hyaluronic acids
are more degraded, more water molecules are drawn into the filler and this leads to main‐
taining the volume much longer than collagen fillers [11,19,20].Because Restylane is a hu‐
man-derived product and there is no need for allergy testing; longevity lasting up to 8
months has been reported [21,22].There are two other formulations of Restylane. Restylane
Fine Line has smaller particle size and has lower viscosity which means it is ideal for more
superficial dermis injections. Restylane Perlane has larger particle size than Restylane and
has higher viscosity and longer-lasting results and is ideal for deep dermal injections [9,17].
Hylaform (Inamed, Santa Barbara, Calif.) and Hylaform Plus were introduced to market and
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were approved by the FDA in 2004 [9].Hylaform is derived from rooster combs [20] and has
smaller amount of hyaluronic acid and higher degree of cross-linking in comparison to Re‐
stylane, which makes its longevity slightly shorter [23]. It also has a small amount of avian
protein that may leads to allergic reaction. It is used for mid dermis injections. Hylaform
Plus has larger particle size than Hylaform, which makes it ideal for deep dermis injections
[9,19].Captique (Allergan, Santa Barbara, Calif.) introduced in 2004 and received FDA ap‐
proval, is a non-animal-derived hyaluronic acid produced bay bacterial fermentation. It is a
cross-linked product and is used for mid to deep dermis injections [9].Juve´derm (Allergan,
Inc., Irvine, Calif.) received FDA approval in 2006. It is a bacterially-derived hyaluronic acid
homogenous gel rather than a particle suspension like other hyaluronic acid products, and
this makes it more biocompatible. It has three different formulations. Juve’derm 24 HV and
Juve’derm 30 HV are highly cross-linked and more highly cross-linked products respective‐
ly, which are used for deeper dermis injections. Juve’derm 30 is used for superficial dermal
injections [9,24].
2.3.1.3. Autogenous fat
First, Neuber used autologous fat for soft-tissue augmentation in 1893. After a period of de‐
cline until 1970s, with the advent of liposuction, autologous fat augmentation again became
popular [8,25]. The main advantage of autologous fat augmentation is that it is autologous,
and there is no risk of allergy reactions. The most important concern about autologous fat
augmentation is its unpredictable results and longevity [25,26]. In contrast to other fillers, it
requires a harvesting procedure, which increases the procedure time and cost [19].
2.3.1.4. Cymetra
Cymetra (LifeCell Corporation, Branchburg, NJ) is a micronized form of acellular dermal tis‐
sue product from human donors called alloderm. It consists of collagen, proteoglycans, and
all components of the dermal tissue with the exception of cells. This product forms a web for
aggregation of fibroblasts to promote collagen formation. Cymetra is a packaged powder
which must be mixed with saline prior to injection. It lasts approximately 3 to 6 months [12].
2.3.2. Semi-permanent fillers
2.3.2.1. Sculptra
Sculptra (Dermik Laboratories, Berwyn, PA) is a synthetic poly-L-lactic acid. It is packaged
as a powder and must be mixed with saline at least 2 hours prior to injection. It is injected
into subcutaneous tissues and is good for correction of deep and large defects. The filler acts
as a web for fibroblast proliferation and collagen production [27].Over-correction of the de‐
fect should not be performed and because of its unpredictability, several touch-up sessions 4
to 6 weeks apart may be needed. Sculpra lasts about 18 to 24 months according to the injec‐
tion site [19].
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2.3.2.2. Hydroxyapatite fillers
Radiesse (BioForm Medical, San Mateo, CA) is an FDA approved filler product containing
calcium hydroxyapatite spheres. It is a viscous product and is used for deep dermis and
subdermal injections [28]. Calcium hydroxyapatite is the mineral component of bones and it
promotes no allergy reactions. These spheres maintain volume augmentation by promoting
collagen production. So there are two mechanisms for maintaining long-term volume. First
is the carrier itself, which degrades after 6 to 8 weeks. However during its degradation, col‐
lagen ingrowth occurs at the injection site and maintains the volume [20]. It is seen that hy‐
droxyapatite particles will become encapsulated by a localized fibroblastic reaction, which is
helpful in limiting particle migrations and maintaining volume [28]. The injected filler is pal‐
pable for about 2 to 3 months until the particles degrade and collagen appears in the site
[19]. Radiance FN consists of hydroxyapatite microspheres in a soluble gel vehicle [29]. It
does not have FDA approval for cosmetic purposes. This product lasts long, therefore no
over-correction should be done [11].
2.3.3. Permanent fillers
2.3.3.1. ArteFill
ArteFill (Artes Medical, San Diego, CA) is an FDA approved product composed of 20% pol‐
ymethylmethacrylate microspheres and 80% bovine collagen as a delivery agent [30]. Be‐
cause of bovine collagen, allergy testing is needed. The delivery agent degrades after about 4
months, but microspheres are permanent and become encapsulated by inflammatory reac‐
tions, which are responsible for 50 to 70 percent of permanent correction and volume main‐
tenance. Overcorrection should not be performed and the patient may need several touch-
up injections spaced 3 to 4 months apart for optimal results [8]. Three to four days following
injection, the microspheres are prone to migration and the patient should avoid facial ex‐
pressions [20].
2.3.3.2. Injectable silicone
Silicone refers to polymers of silicon. Small volumes of Silicone are injected in a grid-like
fashion spaced at 1 to 3 mm into the deep dermis called micro-droplet technique. Several
injections spaced four weeks apart are required for gaining final results. Encapsulation oc‐
curs around particles and is permanent. [31]. Silikon (Alcon Laboratories, Fort Worth, TX) is
an injectable silicone for facial augmentation. AdatoSil (Bausch & Lomb, Rochester, NY) is
another injectable silicone which is more viscous than Silikon.
2.4. Treatment considerations
When injecting fillers, some considerations should be kept in mind. Before injection a combi‐
nation of topical, local and regional anesthesia can be administered. Topical anesthetic
creams must be applied 20 minutes before the injection of local anesthesia. Usually lidocaine
1% with 1:200,000 epinephrine is used.Filler injection around thin skin of eyes and cheeks
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with fine wrinkles is contraindicated; instead resurfacing or chemical peel is needed. Blind‐
ness has been reported with the peri-orbital injection of Zyplast and fat due to intravascular
injection [32-34], therefore the injection should be very superficial, and without extreme
pressure. Allergic reactions occur more in patients with lighter skin. Intramuscular injection
of all fillers is contraindicated because the filler dislocation due to muscle movements. Im‐
plant dislocation can occur during the first three days after injection, therefore early facial
muscle movement should be kept at a minimum. During filler injections the gray of the nee‐
dle should never be visible through the skin, because in this case the needle is very superfi‐
cial and the filler is injected intradermally. Acne or surgical/traumatic scars, which are not
mobile like wrinkles are the only indications for superficial injections. It has been suggested
to cover the lower face during cold weather and exposure to extreme cold. For patients with
dark shadowed eyelids, it has been suggested to augment the orbital rim epiperiosteally by
scratching the needle tip on the bone. Care has to be taken not to inject into the orbicularis
muscle [35]. Regular follow-up is necessary after filler injection. The patient should be visit‐
ed 1 to 2 weeks after injection for evaluation and touch-up corrective injections if needed in
cases of underfill or asymmetry. Touch-up injections also may be needed 1 to 3 months after
injection, when the permanent filler has assumed its final volume and shape [9,11,35].
2.5. Injection techniques
There are 4 commonly reported techniques for filler injection: serial puncture, threading,
fanning and crosshatching.
2.5.1. Serial Puncture
Serial puncture is often used for the glabella injection, philtral column enhancement, lip
augmentation, nasolabial folds and fine wrinkles. In this technique multiple injections are
made serially along the area. First, the skin is held taut and pulled slightly away and out
from the injection area. Then the needle is inserted up to the appropriate depth. The filler
agent is then injected in a small amount. Following that, the needle is removed and reinsert‐
ed along a particular defect and a new injection is made. The injection sites should be close
together, so that the injected filler agents merge into each other [1, 9, 11].
2.5.2. Linear threading
Linear threading is commonly used for lip augmentation, nasolabial fold injection and ver‐
milio-cutaneous border augmentation. In this technique, first, the skin is held taut. Then the
full length of the needle is inserted into the defect to create a channel. Then the filler agent is
delivered slowly and continuously while withdrawing the needle [8,9,11].
2.5.3. Fanning
Fanning injection technique is ideal for large area augmentation such as deep malar injec‐
tion. In this technique several linear threading injections are done in a radial fashion by just
one entrance point for the needle. After full length insertion of the needle and continuous
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injection of the filler while needle withdrawal, just immediately before the needle is with‐
drawn completely, the direction of the needle is changed in a radial fashion, and new lines
are injected the same way. The fanning pattern of lines should be evenly spaced so that the
contour is evenly filled and shaped [9,17].
2.5.4. Cross-hatching
Cross-hatching technique is generally used to fill large defect areas, especially oral commis‐
sures and perioral area. Cross-hatching involves a series of linear threading injections in a
perpendicular fashion to each other. The pattern of lines should be evenly spaced so that the
contour is evenly filled and shaped [9,17].
2.6. Indications
2.6.1. Treating the lips
The lips are the most common areas requested for tissue augmentation. Younger patients
who have enough lip volume usually only need vermilio-cutaneous border enhancement. In
older patients and people with thin lips, volume enhancement is also indicated. Injecting the
lips can provide significant discomfort and usually local anesthesia is needed. Bilateral in‐
fra-orbital blocks are used during upper lip injection and bilateral mental blocks are per‐
formed for the lower lips [36]. Generally, the white roll of Cupid’s bow is injected in the
intradermal or submucosal plane or both. Linear threading and/or serial puncture techni‐
ques are used starting at the oral commissures and proceeding in a lateral to medial direc‐
tion. By using the non-injecting hand to pinch the lip with the thumb and forefinger, the
surgeon can contain the filler to the desired space laterally along the lip. The needle is insert‐
ed at the mucocutaneous junction or slightly on the mucosal side and inserted all the way to
the hub. Care should be taken to avoid superficial injection in this region, as a light blue hue
may become visible. As the needle is withdrawn, the filler is evenly injected into this poten‐
tial space. Finally, the descending legs of the central M configuration are injected to make
sharp angles in the central upper lip. The white roll is also created in the lower lip but is
more curvilinear than in the upper lip. The lower lip is injected in a similar manner but
without sharp angles. The filler is injected in the potential space just beneath the mucosa
across the entire lower lip. Marionette lines are a key element in overall lip enhancement;
otherwise, results are destined to be disappointing to both the patient and the physician
[9,11].Some patients may desire more vermilion volume and want bigger lips as opposed to
simply more-defined lips. Instead of injecting at the vermilion/cutaneous junction, the nee‐
dle is inserted several millimeters below the cutaneous margin and well into the vermilion.
Depending on the desired area to be augmented, the needle is sometimes positioned at the
wet/dry line. Again, the needle is inserted to the hub and slowly withdrawn while continu‐
ous, steady injection is performed. In this area, the goal is to spread a thin, flat layer to
plump the vermilion. The needle can also be placed deeper into the lip when greater volume
is required [11].To enhance the philtral columns, the needle is inserted at the vermilion/cuta‐
neous junction in the intradermal plane and directed all the way to the base of the ala. The
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skin is then pinched with the non-injecting hand to create a triangle. Less filler is injected
near the alar base, with more filler injected toward the vermilion border. By pinching the
skin with the non-injecting hand, the injected filler can be formed into the specific shape. In‐
travascular injection could cause lip necrosis. Notice that the artery lies in the posterior one
third of the lip at about the level of the incisal edge of the anterior teeth. This level also cor‐
responds with the vermilion/cutaneous junction on the facial surface of the lip [11,37].
2.6.2. Injecting oral commissures
Aging causes oral commissures to become depressed and also causes a down-turned smile.
Oral commissures are where multiple tissue planes and muscles converge together and this
makes it difficult to augment; usually a significant amount of filler material is necessary [11].
This area is augmented using the cross-hatching technique. In this area, filler must be inject‐
ed into multiple layers. The filler must be injected deep to create a base, then the rest of the
filler is injected on top of it interadermally [9].
2.6.3. Injecting perioral rhytids
Perioral rhytids which are also call lipstick lines, are usually treated by just white roll and
lip augmentations. By doing this, most of the rhytids are fade because of stretching of the
skin. If this does not solve the problem, rhytids are treated individually by injecting fine par‐
ticle-sized filler agents intradermally using linear threading technique. The needle is insert‐
ed into the rhytide at the vermilio-cutaneous junction, and the filler is injected while
withdrawing the needle [11].
2.6.4. Injecting the nasolabial folds
The nasolabial fold is a normal and natural anatomic structure present even in young peo‐
ple. Aging causes the nasolabial fold to deepen and the treatment goal is to improve it not to
make it disappear. This area is treated by injecting filler (Figure 1-A) using serial puncture
or linear threading technique or the combination of both. The patient should always be seat‐
ed upright and the filler is injected into the mid to deep dermis beginning inferiorly and
moving superiorly. It is important to be careful not to inject the filler material into the lateral
side of the nasolabial fold, which makes the fold look deeper. Using linear threading techni‐
que, the needle is inserted into the fold and the filler is injected while withdrawing the nee‐
dle. For serial puncture technique augmentation, a small amount of filler is injected along
the nasolabial fold [9,11].
2.6.5. Glabellar folds
The mobility of the muscles of this area can decrease the longevity of the filler; therefore it is
recommended to treat this area with a combination of filler augmentation and botulinum
toxin injections; this can increase the longevity as long as nine months. This area is usually
treated by injecting the filler using serial puncture technique into the mid-dermis of the
wide and deep rhytids, and injecting fine-sized particle filler using linear threading techni‐
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que into the dermal-epidermal junction of the narrow and fine rhytids. Compressing the su‐
pra-trochlear vessel with the non-injecting hand is necessary to prevent intravascular
injection of the filler agent [9].
2.6.6. Forehead lines
Linear threading technique is usually used for the treatment of forehead rhytids. Fine-sized
particle fillers are used for injection into the dermal-epidermal junction of this area. In the
glabellar region, because of the activity of the muscles of this area, combination therapy of
this area with botulinum toxin injection is preferred for longevity of the results [9].
2.6.7. Tear trough/malar region
For augmentation of this area, large-sized particle fillers are used for supra-periosteal injec‐
tion using linear threading or serial puncture technique (Figure 1-B,C). For deep rhytids of
this area, filler augmentation alone may not be effective enough and face lift surgery may be
needed [9].
 
A B C
Figure 1. Filler agent injection. A, B, C, The injectable filler agent is used for the augmentation of the nasolabial folds,
malar region and tear trough region respectively.
2.7. Post – operative care
There are several post-treatment considerations that patients should mind following filler
injection. The patients are recommended to use cold compresses for 24 to 48 hour to reduce
swelling and the patient should have 30 degrees head elevation for the first 24 hours. Physi‐
cal activities and facial expressions should be limited immediately after injection to prevent
filler migration. They also should avoid excessive sun exposure until erythema and swelling
disappears.Aspirin, NSAIDs and blood-thinning medications should be avoided for 24 to 48
hours before and after injection to minimize the bruising which may last 7 to 10 days. Acet‐
aminophen is usually enough for pain control. Oral antihistamines can blunt the histamine
release and resultant early edema and may be most useful in patients who develop more
edema than usual or redness immediately after injection. Swelling occurs following injection
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and usually last for 2 days but it may continue for up to 3 weeks. Oral antihistamines can
help to decrease the early edema [1,8,9,17].
2.8. Complications
Pain is common following injection. Using small needles can decrease the injection pain, but
viscous filler agents may require larger needles for injection. It is also recommended to use
topical or regional anesthesia prior to filler injection to reduce injection discomfort [8,38].
Acetaminophen is also effective to manage post-injection pain, but aspirin or NSAIDs are
contra-indicated due to their anticoagulation effects and they should be discontinued prior
to injection if possible. Blood-thinning medications are also no exceptional because of their
ability to increase the risk of bleeding. Post-operative infections are rare, but people with the
history of herpes simplex infections should be treated with prophylactic antiviral agents
[1,8]. Granuloma formation is common with alloplastic filler agents and semi-permanent
and permanent materials, but it is also reported with using biologic filler agents [39-41].
Granulomas can often be treated with simple excision and incision/drainage. Hyaluronidase
is also recommended for hyaluronic acid fillers [40,42]. To prevent complications such as
filler palpability and lumps, care should be taken to inject more viscous and large-sized par‐
ticle filler agents into the deep dermis and less viscous and small-sized particle filler agents
more superficially [8].Major complications are rare but serious. Allergic reactions can occur
with animal-derived products and allergy testing prior to injection of these materials is re‐
quired [41,43]. Some other serious complications such as skin necrosis, blindness and death
are also reported [1,8,13].
3. Autologous fat transfer
As mentioned previously, ideal fillers should be safe, efficient, easy to use and biocompati‐
ble. Autologous fat is the closest to an ideal filler. It is autologous and therefore biocompati‐
ble and non-immunogenic, it is available and inexpensive and it can be easily acquired
through a minimally invasive procedure [44-47].Fat tissue transfer has become a commonly
used technique because of its advantages. One of its disadvantages is its longevity and sur‐
vival rate, which is very unpredictable and survival rates between 40 to 80 percent have
been reported [48-51].
3.1. Background
Autologous fat grafting, first performed in 1890s, and as injectable filler in the 1920s [1,52].
In 1893, Neuber first described the free autologous fat graft transfer for soft tissue augmen‐
tation. He transferred tiny parcels of fat into the scar tissues and studied their survival and
reported that smaller grafts survived longer with more predictable results. Silex, Axenfeld
and Verderame have also separately studied free abdominal fat grafts for treating depressed
skin scars as a result of tuberculosis [53].In 1912, Hollander described changes after fat injec‐
tion in patients with facial lipo-atrophy [54]. In 1926, Miller described the methods for fat
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injection via cannulas [52]. Neuhof performed several studies on fat graft survival and re‐
ported that with time the graft cells die and are replaced by fibrous tissue [55]. In 1956, Peer
mentioned that good blood supply at the recipient site and the need for hemostasis are im‐
portant factors for graft survival [56]. In 1997, Coleman introduced his modified technique
for atraumatic fat harvesting, centrifugation and injection to maximize survival rate [57].
3.2. Indications
The fat transfer technique can be used for the correction of facial asymmetries. Today, it is
also used for cosmetic purposes, as a filler for facial rejuvenation.
3.3. Fat harvesting
3.3.1. Donor site
The most common fat harvest sites include the abdominal wall, extremities, trochanteric
area, inner knee, dorsocervical fat pad, and flank sites. There is no evidence to claim that
which donor site is optimal for far harvesting [50,58]. Rohrich et al. found no difference be‐
tween the viability of the fat cells harvested from abdomen, flank, thigh and medial knee
[58]. According to this, the donor site is usually chosen for ease of access and availability.
Lower abdomen and the thighs are the most two easily accessible sites for fat harvesting be‐
cause these sites do not require patient repositioning and redraping (Figure 2).
3.3.1.1. Lower abdomen
The central part of the abdomen, in the lower and upper region usually contains low con‐
tents of fat for harvesting. The harvesting should be kept minimized in the midline to pre‐
vent contour irregularity. The cannula should be entered into the lower abdomen while
feathered upward and outside into the upper-lateral abdomen. It is important harvest the
upper abdomen beyond the lateral limit of the lower abdomen to prevent the occurrence of
contour irregularities [59].
3.3.1.2. Inner thigh
Fat can be harvested from inner thigh by performing a stab incision along the inguinal line.
Then the cannula is inserted. The shadow of the cannula should not be visible through the
skin, which means that the cannula is very superficial and harvesting will lead to contour
irregularities. The harvesting should be feathered out toward the anterior thigh to minimize
contour changes [59].
3.3.1.3. Anterior thigh
The anterior thigh has variable amounts of fat in different patients and can be accessed
through the same access point as for the inner thigh [59].
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3.3.1.4. Lateral thigh
The lateral thigh is accessed via a stab incision made laterally along the inguinal line and the
harvesting is performed inferio-laterally.
3.3.1.5. Inner knee
This is an easy area to harvest and usually is used only in very thin patients with low fat
reserves. A stab incision is made in the medial, inferior and posterior portion of the fat pad
and the cannula is inserted in an anterio-superior direction for fat harvesting [59].
3.3.1.6. Buttock
The buttock can be used in the very thin patients with low fat reserves, because everyone
has some fat in the buttock. The reason that this area is not commonly used for fat harvest‐
ing, is that it needs patient repositioning and redraping. The stab incision should be made
along the buttock crease to minimize the scar and pigmentation of the skin [59].
3.3.1.7. Lower back
The lower lateral back is another area for fat harvesting in thin patients. The incision should
be made along the lower lateral skin fold to harvest the lower back fat [59].
3.3.1.8. Triceps region
This area is also usually used in thin patients. The stab incision is made on the back of the
arm, near the elbow, along the triceps for fat harvesting. Over-harvesting this area can lead
to contour irregularities [59].
3.3.2. Local anesthesia
Moor et al. studied the effect of epinephrine and lidocaine on human fat viability and they
mentioned that it had no adverse effect on fat cells [60]. Fat harvested with normal saline,
lidocaine and epinephrine solution has no significant effect on cell viability [61-65]. Today,
most clinicians inject the donor site with local anesthetic. Some surgeons however, do not
use any local anesthesia to avoid exposing the fat cells to lidocaine, which has been shown
to temporarily restrain adipocyte growth in cell culture [60]. For patients who are under
deeper levels of sedation or under full general anesthesia, a mixture of 5 ml 1% lidocaine
and 1:100,000 epinephrine with 15 ml plain saline is enough. Half of the mixture is placed
deeper to the fat plane, and the other half is distributed superficially into the subcutaneous
plane [59].
3.3.3. Aspiration technique
Rohrich et al. harvested fat using traditional liposuction, internal ultrasound-assisted lipo‐
suction and external ultrasound-assisted liposuction and they found that internal ultra‐
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Figure 2. Autologous fat transfer. A, Blood is collected from the patient for PRP preparation. B, The donor site is inject‐
ed with local anesthetic solution. C, The fat graft is aspirated with a cannla connected to syringe. D, Syringes contain‐
ing aspirated fat graft. E, Harvested fat graft after washing with lactated Ringer’s solution. F, PRP is added to the graft
to increase its longevity. G, The fat graft is delivered into the insulin syringe for reinjection. H, The tear trough area is
augmented with PRP injection. I, J, K, L, The fat graft is injected into the nasolabial groove, lips, jowl and malar areas
respectively.
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sound-assisted liposuction can lead to thermal liquefaction of the fat cells [67]. Shiffman and
Mirrafati compared various cannulas, needles and suction pressures due their effect on cell
viability and found that vacuum pressure more than 700 mmHg can lead to cell damage
[68]. Leong et al. found no difference between syringe liposuction and pump-assisted lipo‐
suction in cell viability [69].Ozsoy et al. compared the effect of different cannula diameter in
the cell viability and found that larger cannula leads to more viable cells [70,71]. Pu et al.
compared the effect of fat harvesting using Coleman technique versus liposuction technique
in the cell viability and found more viable cells in the Coleman technique group (use of a 3-
mm cannula connected to a 10-cc syringe with manual suction via withdrawing the plunger)
[72]. Conventional liposuction cause up to 90 percent fat cell rupture [73]. Carpaneda and
Ribeiro mentioned the benefits of tiny particle fat grafts aspiration. They mentioned that the
graft thickness was inversely proportional to the survival rate of the graft if its thickness ex‐
ceeds 3mm [74]. As discussed above, syringe aspiration is currently the most popular fat
harvesting technique. After the patient has been sedated, prepared and draped, the anes‐
thetic material is injected into the donor site and a 3 mm stab incision is made into a discreet
area. A blunt 2-hole cannula attached to a 10 cc syringe in used for harvesting the graft by
applying a gentle negative pressure by retracting the syringe plunger [50,64,66,75]. The can‐
nula should be move inside the donor site, in the curetting action fashion to let the small fat
parcels enter the cannula [75]. The non-dominant hand should be used to stabilize the fat
pad during cannula movement with the palm flat on the skin. After a few passes of the can‐
nula along one straight path, the cannula should be withdrawn but not completely and then
the cannula should be redirected to the adjacent linear path.
3.4. Preparation
3.4.1. Centrifugation / washing
Coleman stressed the importance of removing nonviable components of fat aspirate such as
oil, blood, and lidocaine by sedimentation or centrifugation at 3000 rpm for 3 minutes [45].
Centrifugation and washing are both aspects of fat graft preparation that have been exam‐
ined for greatest graft success. Butterwick and others compared centrifuged versus non-cen‐
trifuged fat, grafted in hands and found that the centrifuged fat showed more longevity
[76,77]. Ferraro et al. evaluated fat grafting in patients using 1300 rpm for 5 minutes showed
less resorption in patients grafted [78-80].Rohrich et al found no difference in adipose viabil‐
ity between non-centrifuged fat and fat that underwent the centrifugation (500 g for 2 mi‐
nutes) and challenged the role of centrifugation [58]. Xie et al. found that the increased
centrifugal force, especially greater than 1145 g, significantly decreased the viability of cells
[81]. Ramon et al. also found no difference between centrifuged fat grafts in comparison to
fat harvested after the use of a sponge to wipe away fluids, debris and oil [82]. Karacalar et
al. introduced fat harvesting technique in a bloodless field by using a pneumatic tourniquet
to eliminate the need for centrifugation [83]. Washing harvested fat before injection has also
been described as a means of enhancing graft survival. Marques et al. used washing techni‐
que instead of centrifugation. They used lactated Ringer’s solution to wash the harvested fat
A Textbook of Advanced Oral and Maxillofacial Surgery776
and reported increased graft survival rate [84]. It has been stated that washing, will elimi‐
nate the inflammatory components from the graft.
3.4.2. Addition of growth factors
The addition of growth factors and nutrients to the harvested fat is not advocated by many.
Coleman emphasized to prevent damage to the delicate fat grafts and opposed the addition
of chemicals, hormones, drugs, or foreign substances to it [57]. Karacalar et al. [83] and
Nordstrom [64] advised not to add any growth factors to the harvested graft. In contrast,
some studies proposed the addition if supplements to improve the fat survival [85]. Har-
Shai et al. proposed the suspension of the fat graft in a nutrient cell culture supplemented
with non-steroidal anabolic hormones, insulin, thyroxin, and growth hormone [86]. Yuksel
et al. delivered a relatively continuous dose of insulin, IGF-1, basic fibroblast growth factor
(bFGF), or varying combinations to inguinal fat grafts and found increased fat graft weight
and volume [87].
3.5. Fat reinjection
It is believed that the method of injection has great effect on the success and longevity of
treatment [51,75]. The injected fat should be within 2 mm of an arterial blood supply. This
will increase the fat survival and minimize graft necrosis and scar tissue formation [65]. But‐
terwick and Lack described a technique known as “fat autograft muscle injection” that in‐
volved using blunt-tipped cannulas for fat injection directly into the intrinsic facial muscles
[88]. Nordstrom described a “spaghetti” fat grafting technique in which 3 mm grafts were
laid down in tunnels that did not touch each other [64]. To maximizing the surface area of
the graft in contact with blood supply, injecting small particles of fat in multiple tunnels in a
fanning fashion has been proposed [53]. this technique involves the creation of multiple tun‐
nels by inserting the cannula through a 2 mm stab incision and then injecting small fat parti‐
cles during cannula withdrawal (Figure 2). Coleman uses a 17 gauge blunt cannula
connected to syringe [45], but the use of a 14 gauge blunt tip or curved micro-cannula is also
suggested [47,65,89]. Tzikas used a 16 gauge, bullet-tipped, one-hole cannula for injection
[66]. Trepsat used a 0.3 mm cannula attached to a 1 cc syringe for upper lid injection from
the deep layer near the bone to a superficial layer just under the orbicularis oculi muscle. He
also used a fine 19 gauge cannula on a 1 cc syringe for the lower lid to lay down fat cells in a
multi-pass, pre-tunneled areas of the sub-orbicularis oculi fat [90].
3.6. Fat graft survival
Fagrell et al. compared the longevity of the excised fat grafts, fat harvested in a cylinder
shape with a 4.5 mm cannula, and fat grafts aspirated with a 2 mm cannula and found 60
percent weight loss in the aspirated group, 1 percent in the excised group and 2 percent in
the cylinder group [91]. Coleman believes that stabilization of the graft volume occurs 3 to 4
months after injection and remain constant for 8 to 12 years [75].
Office – Based Facial Cosmetic Procedures
http://dx.doi.org/10.5772/53882
777
3.7. Fat storage
Lidagoster et al. compared fresh, refrigerated (1°C), and frozen (–16° C) fat specimens inject‐
ed 1 to 2 weeks after harvesting, with a group that underwent immediate injection. They
found more inflammation and less viable fat in the stored group in comparison to the imme‐
diately injected group [92]. Butterwick et al. compared fat augmentation by using freshly
isolated fat with frozen fat (–40°C) and found no difference in the esthetic results between
them at 1, 3, and 5months [93]. It has been reported that even brief exposure of the fatty tis‐
sue to air causes up to 50 percent of it undergo cytoplasmic lysis [94]. MacRae et al. com‐
pared the differential effect of incubation temperature on the fatty tissue viability versus
storage at low temperature and they found that viability was superior in the frozen group
[95]. Pu et al. found that there was no difference between fat graft mixed with cryoprotective
agent and fresh fat graft in terms of cell viability [96].
3.8. Complications
Fat injection has some minor common complications such as edema and bruising with are
transient and can be minimized by head elevation, compression and anti-inflammatory
medicines. Using blunt cannula can minimize the damage to the underlying tissues and
minimize the edema. Infection is rare using sterile technique. A rarely reported esthetic
complication is the overgrowth of the graft [97-99]. Liposuction deformities may occur if the
donor site is not correctly chosen. The most severe complications reported include fat embo‐
lism with subsequent blindness, aphasia, motor restriction and even acute fatal stroke
[32,100-103].
4. Botulinum neurotoxin injection
Hyper-dynamic contraction of the facial muscles cause overlying skin folds perpendicular to
the direction of the muscles. These facial folds produced by muscle contractions cause dy‐
namic wrinkles. Dynamic wrinkles are best treated with botulinum toxin injections.
4.1. Background
Justinus Kerner, first described a case of lethal food poisoning particular to poorly-prepared
meat products. The symptoms were mydriasis, diplopia, gastrointestinal problems and mus‐
cle paralysis. He named the causative poison botulism [104,105]. In 1897, Emile van Ermen‐
gem, isolated the causative pathogen, later named clostridium botulinum
[106-108].Clostridium botulinum is a gram-positive spore-forming bacillus. In 1949, neuro‐
muscular blockade was described as the mechanism of action of the botulinum neurotoxin
[109]. In 1973, Scott et al, studied the therapeutic effect of botulinum neurotoxin type-A
(BoNT-A) in primates [110]. In the 1989, Alan Scott used this toxin in human to treat strabis‐
mus and blepharospasm [111,112]. Oclulinum received FDA approval in 1989 for the treat‐
ment of strabismus, blepharospasm and hemi-facial spasm in 1989, which was then
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renamed by Allergan (Irvine, USA) company to Botox Medical. In the same period, Ipsen
(Slough, UK) introduced Dysport to European markets [113]. In 1992, Carruthers and Car‐
ruthers observed the improvement in peri-orbital wrinkles in patient treated for blepharo‐
spasm using Botox and they discovered a new treatment indication for BoNT [113]. Since
then, many published the cosmetic use of BoNT [113-116]. In 1999 and 2000, Niamtu intro‐
duced the cosmetic uses of BoNT in maxillofacial practice [117,118]. Botox Cosmetic, re‐
ceived FDA approval for the glabellar region in 2002 [108].
4.2. Bacteriology
As mentioned earlier, Clostridium Botulinum is an anaerobic, gram-positive, spore-forming
bacillus which produces exotoxin. Based on their exotoxin antigenic specificity, eight sero‐
types of this bacterium are recognized: A, B, C1, C2, D, E, F and G [106,119,120].Neurotoxin
strains A, B, E, F and G can affect humans [121,122]. Neurotoxin strains A and B are antige‐
nicity different, but they have similar functions and are commercially available for medical
treatments [108,123]. Although these toxins are antigenically different, there are some serum
cross-reactivity among them and with tetanus toxin, because of some similar homological
sequences [124].
4.3. Structure and toxicity
BoNT is a high-molecular weight protein complex made of 3 different proteins: First, a 150-
KDa toxin which itself is composed of a 100-kDa heavy chain and a 50-kDa light chain that
are binded together with disulfide non-covalent bonds. This bond disrupts during toxin ac‐
tivation. Second, a non-toxin hemagglutinin protein, which protects the toxin from being de‐
stroyed by acids. Third, a non-toxin non-hemagglutinin protein [125]. Clostridium
botulinum spores are heat resistant and can survive in inadequately processed foods and
can produce toxin, which can cause food-borne botulism [126]. Symptoms of toxin poison‐
ing include weakness, vertigo, diplopia, difficult speaking and swallowing, difficult breath‐
ing, muscular weakness and constipation. These usually appear 18 to 36 hours after food
poisoning [108].The lethal dose of BoNT in humans is not known exactly, but according to
animal studies the LD50 (lethal dose for the death of 50% of population) for a 70 kg human
is estimated about 0.09–0.15 mg by intravenous injection, 0.7–0.9 mg by inhalation and 70
mg by oral administration [122,127,128]. The standard vial of BoNT-A has a lethal dose 200
million times less [129].
4.4. Mechanism of action
Facial muscle contractions are responsible for the creation of dynamic facial folds. When the ac‐
tion potential passing along a nerve reaches the nerve ending; it causes acetylcholine vesicles to
attach to the nerve ending membrane and then acetylcholine is excreted from the nerve ending
membrane, into the neuro-muscular junction. Acetylcholine fuses to the muscle membrane and
causes muscle contractions [130].When BoNT is injected on neuromuscular junction, its heavy
chain binds to the cell membrane of the nerve ending and creates a passage for the light chain to
enter the nerve ending via endocytosis and vesicle formation. These toxin-containing vesicles
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inhibit the acetylcholine release from nerve endings. As mentioned earlier acetylcholine is re‐
sponsible for muscle contraction. Without acetylcholine release, muscle contraction is inhibited
and leads to reversible muscle atrophy [131-134]. By doing this the facial muscles which are re‐
sponsible for facial dynamic folds, will become paralyzed. The paralytic effect of BoNT is dose-
dependent. BoNT effects usually take 2 to 3 days to appear after injection and its maximum
effects occurring 1 to 2 weeks later and then level off slowly until full nerve recovery within 3 to 6
months following administration [119,135-137]. This nerve blocking effect of BoNT is perma‐
nent but the reason for the loss of effect after 3 to 6 months is due to synaptic switching and
spouting of new axon terminals and the re-establishment of neuromuscular transmission
[108,133,138,139].It is seen that BoNT can diffuse across fascial planes to surrounding muscles,
which can cause weakening of the surrounding muscles not injected and creates a flaccid area
larger than the area of muscle denervation [140].
4.5. Preparations
There are several BoNT preparations in different countries. The most common available
BoNT-A preparations are Botox, Dysport, Xeomin, Prosigne and PurTox. Myobloc is a
BoNT-B preparation. The treatment dose varies for each brand of toxin and for different
parts of the body.
4.5.1. BoNT-A
Botox was first produced by Allergan Inc, USA in 1968 for the treatment of strabismus
which was originally called Oculinum. Then in 1991, Allergan Inc. renamed it Botox
[106,110]. Each vial of Botox contains 5 ng (100 U) of air-dried BoNT-A, 500 μg of albumin
and 900 μg of sodium chloride [141].
Dysport produced by Ipsen Limited, UK is a cosmetic product mostly available is Europe. Each
vial of Dysport contains 12.5 ng (500 U) of air-dried BoNT-A, 125 μg of albumin and 2.5 μg of lac‐
tose. It is important to remember that because of different type and strain of bacteria used for the
production of Botox and Dysport, their doses are equivalent to each other [141].
Xeomin is a freeze-dried powder of BoNT-A without any accessory proteins produced by
Merz Pharmaceuticals GmBH, Germany. Because in contrast to other BoNT-A products, it
does not contain additive proteins, it is less immunogenic and can be used when large
amounts of BoNT are required to be injected [142,143]. Botox and Xeomin have similar dose-
dependent paralytic effects and their diffusion to the surrounding muscles are low [144].
Prosigne is a BoNT-A product made by Lanzhou Biological Products Institute, China, in
1993 and is only available in China [145].
PurTox is a purified BoNT-A which is produced by Mentor Corp, Santa Barbara, CA, USA [143].
4.5.2. BoNT-B
Myobloc is a BoNT-B product made by Solstice Pharmaceuticals, South San Francisco, CA,
USA [141]. Myobloc has received FDA approval of the treatment of cervical dystonia and
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hemi-facial spasm in 2001, but it does not have cosmetic approval, and its cosmetic use is
off-label [146]. It is usually used for cosmetic purposes when the patient shows resistance to
BoNT-A products [141,147-150].
Each 0.5 cc vial of Myobloc contains 25 ng (2500 U) of BoNT-B, 1.0 cc vial contains 50 ng
(5000 U) and 2.0 cc vial contains 100 ng (10,000 U). Each product is pre-constituted in solu‐
tion with 0.05% albumin [141]. Several studies have shown that the duration of action of
BoNT-B is shorter than BoNT-A, and it has a less predictable diffusion pattern [141,150-152].
4.6. Indications
BoNT is used for cosmetic purposes in the face for dynamic folds and should be injected in
areas with dynamic muscle contractions, such as the glabellar region, frontal region and
peri-orbital lines (Figure 3). It is also used for the treatment of gummy smile [137,153-155].
 
A B C
Figure 3. Botulinum neurotoxin injection. A, B, C, The BoNT is injected for the treatment of the glabellar rhytids, peri-
orbital rhytids and horizontal forehead rhytids respectively.
4.7. Contra – indications
BoNT should not be injected to pregnant women and nursing mothers. Patients who are tak‐
ing aminoglycoside antibiotics, quinine, calcium channel blockers, magnesium sulfate, succi‐
nylcholine, polymyxin, cyclosporine and cholinesterase inhibitors should not be given
BoNT, because these may potentiate the effect of the toxin [122,136,156]. BoNT injection is
also contra-indicated in patients with neuromuscular disorders such as myasthenia gravis,
amyotrophic lateral sclerosis and Lambert-Eaton syndrome. BoNT administration is also
contra-indicated in patients who may have hypersensitivity to BoNT or to any of the addi‐
tive ingredients [157,158].
4.8. Dosage
There are several brands of BoNT-A products available, but Botox (also known as Botox Cos‐
metic, Vistabel, and Vistabex) is the most well-known brand. Botox should be kept frozen prior
to use. The manufacturer recommends reconstitution of the vial with sterile injectable normal
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saline. The reconstituted toxin should be stored at a temperature of 2 to 8 ˚ C and should be inject‐
ed within 4 to 8 hours [136]. This concern is mostly about its sterility. Although there are some
reports that shows no bacterial contamination even after 15 days [159,160].The reconstitution
should be done by gently injecting the diluent into the toxin vial to avoid foam formation, which
can compromise the effectiveness of the toxin. The volume of the diluent to be injected into the
toxin vial differs according to the injection site and desired concentration, the number of units to
be injected, the clinician preferences and muscular mass. It is seen that injecting higher doses of
toxin in smaller volumes prevent the toxin from diffusing around and keeps the toxin effects lo‐
calized, but when there is a need to treat a large area such as the forehead injecting higher doses
in smaller volumes is hard to do [131,161-163].Male patients usually have larger muscle vol‐
umes than female patients and they need more units of toxin to be injected to achieve the same
effects as female patients. [162,164,165].
4.9. Injection technique
For maximal effect, the toxin should be injected into the mass of the muscle which causes
skin folds, not into the skin folds and depressions. This is achieved by identifying the causa‐
tive muscle when examining the patient at rest and maximal facial muscle contraction situa‐
tion [136].The injection technique is simple. The injection should be performed intra-
muscularly and should avoid superficial intra-dermal injections. Usually there is no need for
anesthesia, but if the patient insists topical anesthetics can be used at least 45 minutes before
injection [136,166].
4.10. Applications
4.10.1. Glabellar rhytids
Deep vertical folds of the glabellar region which are also called frown lines are best treated
by BoNT injection [136]. Corrugator supercilii muscles with contribution from the frontalis,
orbicularis and procerus muscles are responsible for these dynamic folds, but with aging,
these folds become static. Orbicularis oculi and corrugator supercilii muscle are responsible
for adduction of the brows. Depressor supercilii and procerus muscles cause brows to move
inferiorly [136,167,168].The physician asks the patient to frown to be able to palpate and
identify the muscles. The corrugator supercilii muscle should be injected about 1 cm above
the orbital rim in the mid-pupillary line to prevent toxin diffusion into the medial part of the
brows which can cause brow ptosis [136,169]. The dermal insertion of the corrugator muscle
should also be assessed, because it determines the lateral extent of the toxin injection. Injec‐
tions just above the brow in the mid-pupillary line must be avoided because they will cause
eyelid ptosis [156]. The toxin effects usually last for 3 to 6 months. Male patients may need
more doses of toxin due to their greater muscular mass [162,165].
4.10.2. Horizontal forehead rhytids
The frontalis muscle is a large muscle which originates superiorly to the brows. Its contrac‐
tion causes horizontal forehead folds. These folds can be treated by injecting BoNT into the
A Textbook of Advanced Oral and Maxillofacial Surgery782
frontalis muscle (Figure 4). The injections should be made higher than half way between the
hairline and brows, because lower injections can cause brow ptosis. Injections are done at 5
to 7 sites distributed horizontally, 2 to 3 cm above the eyebrows. The injections should ex‐
tend laterally enough at the lateral part of the brow to prevent the lateral part of the eye‐
brows being pulled up excessively, but not more than 2 cm lateral to the most lateral part of
the eyebrow [136,170-172]. For patients who want elevation of the lateral part of the brows,
these areas should not be injected [169,173,174]. The effects of the toxin injection usually last
for 4 to 6 months [175]. The side effects, such as headache, eyelid swelling, and brow ptosis,
are more common with higher doses, but it has been shown that lower doses are prone to
faster relapse [167,176].
Figure 4. BoNT injection into the frontalis muscle.
4.10.3. Brow lift
Contraction of the corrugator supercilii, procerus and the medial portion of the orbicularis
oculi causes inferior positioning of the medial part of the brow. Contraction of the lateral
portion of the orbicularis oculi is responsible for inferior positioning of the lateral part of the
brow. As mentioned earlier, treating the forehead folds can also causes eyebrow elevation
[175].Injecting the procerus muscles and the supero-lateral portion of the orbicularis oculi
could also causes eyebrow elevation. The injection is done at the temporal fusion line, below
the lateral third of the brow and superior to the orbital rim [167,173].
4.10.4. Eyebrow asymmetry
There are some conditions that could cause eyebrow asymmetry, such as unilateral facial
nerve palsy, uneven brow lift surgery, hemi-facial paralysis and the patients with binocular
vision combined with ipsilateral brow ptosis. In these cases, unilateral injection of the proce‐
rus and lateral portion of the orbicularis oculi with the BoNT at the inferiorly positioned
eyebrow side, can improve the condition [177].
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4.10.5. Peri – orbital rhytids
Contraction of the lateral portion of the orbicularis oculi muscle is responsible for the devel‐
opment of the peri-orbital folds at the lateral side of the orbit, which are also called crow’s
feet appearance. At first, they are only dynamic folds, but by aging, muscle activity and sun
exposure they became static [136,137].
For treating these folds, three injections should be done in the lateral portion of the orbicula‐
ris oculi muscle. The injection sites are identified while the patient is smiling. It is important
for these injections to be at least 1 cm lateral to the lateral orbital rim, to prevent the diffu‐
sion of the toxin into the orbit. The upper most injection site is just below the eyebrow and
the lower most site is 1 to 2 cm lower to the first one [178,179]. The injections should be done
when the patient is relaxed and not smiling to prevent the diffusion of the toxin into the zy‐
gomaticus muscles which causes upper lip ptosis [180]. The injections should be superficial
to prevent injecting the toxin into the orbital septum, which could migrate into the ocular
muscles and cause diplopia [181].
4.10.6. Hypertrophic pre – tarsal orbicularis
Injecting the pre-tarsal orbicularis muscle with BoNT can widen the palpebral aperture for
better esthetic appearance. The injection is done 3 mm inferior to the lower pre-tarsal orbicu‐
laris oculi muscle both at rest and while smiling [167,179].
4.10.7. Nasalis muscle
Nasalis muscle has 2 parts. The upper nasalis muscle extends inferio-laterally from the boy
dorsum of the nose to the skin lateral to the nose. Its contraction is responsible for the devel‐
opment of fanning-shaped, radial folds of the skin lateral to the nose, which are called “bun‐
ny lines”. The lower nasalis muscle extends into the lateral portion of the nasal ala and its
contraction causes nostrils to dilate. Some patients might be unsatisfied of these contrac‐
tions, especially because these contractions are usually involuntarily. This condition can be
treated easily by injecting toxin into the nasalis muscle. The injection site should be superior
to the nasofacial groove and anterio-inferior to the angular vein [167].
4.10.8. Gummy smile
There  are  several  reasons  that  could  make  a  patient  have  a  gummy smile  appearance.
One of its reasons is the hyper-functionality of the upper lip elevating muscles. The leva‐
tor labii  superior aleque nasi  muscle,  the levator labii  superior muscle and zygomaticus
minor  muscles  are  responsible  for  the  elevation of  the  upper  lip.  By injecting the  toxin
into  these  muscles,  their  tonicity  can  be  reduced,  which  could  treat  the  gummy  smile.
The  toxin  is  injected  lateral  to  each  nostril,  which  can  cause  relaxation  of  the  muscles.
Weakening  of  these  muscles  decreases  the  amount  of  lip  elevation  and  decreases  the
amount of gingival show [137,182].
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4.10.9. Perioral rhytides
Contraction  of  the  orbicularis  oris  muscle  is  responsible  for  the  creation  of  the  vertical
perioral folds. This muscle encircles the mouth and acts as a sphincter which causes the
lip to close. For treating these folds, several micro-dose injections into the orbicularis oris
are required to weaken this muscle. Usually 6 to 8 injections are required to accomplish
this [167].
4.10.10. Mid – facial asymmetry
There are two functional reasons for producing mid-facial asymmetry: the hyper-function
of the muscles of one side, or the hypo-function of the muscles of the other side. These
patients  can be  treated by injecting toxin  into  the  zygomaticus  muscle,  risorius  muscle,
orbicularis  oris  and  masseter.  In  patients  with  hemi-facial  spasm,  the  facial  midline
moves  toward  the  hyper-functional  side,  and  the  muscles  of  the  hyper-functional  side
should be injected for the correction of the facial midline. In contrast, in patients with fa‐
cial nerve paresis, the midline moves toward the normal side, the normo-functional side
muscles should be injected [167].
4.10.11. Depressor anguli oris
The depressor anguli oris muscle originates from modiolus and extends inferiorly into the
inferior border of the mandible. Its contraction is responsible for the inferior movement of
the mouth corners. Its hyper-functionality leads to a constant downward turn of the mouth
corners and constant bitter appearance. Because of its origin, which is in close proximity to
other muscles, it should not be injected directly. It is proposed to inject this muscle at the
level of the mandible, at its posterior margin and close to the anterior margin of the masseter
muscle [167]. Because the upward motion of the mentalis muscle is also responsible for this
bitter appearance, the injection of this muscle is also advisable.
4.10.12. Mental crease
Hyper-functionality of the mentalis muscle can cause a deep mental crease and unesthetic
appearance. Weakening this muscle can softens this crease. To accomplish this, toxin should
be injected into this muscle, at each side of the midline and below the mental crease. Injec‐
tions above the mental crease can cause perioral muscle weakness [167].
4.10.13. Lower facial asymmetry
Lower facial asymmetry is usually seen in patients with hypo-functionality of one side of
the face. This hypo-functionality can be due to a surgical procedure, traumatic cutting of the
orbicularis oris or risorius muscles, congenital or acquired weakness of the depressor anguli
oris muscle, or due to innervation problem. To treat this condition, the risorius muscle at the
normo-functional side should be injected with BoNT [167].
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4.10.14. Masseteric hypertrophy
Para-functional habits such as bruxism and clenching can lead to hypertrophic masseter
muscles, which can cause an unesthetic appearance. This condition can be treated by inject‐
ing BoNT into the masseter muscle to reduce its tonicity and its mass, but the para-function‐
al habits should be first treated prior to BoNT injection. Each masseter is injected in 3 to 6
sites in the thickest part of the muscle at the inferior mandibular border, with low dose tox‐
in. The muscle can be palpated by asking the patient to clench the teeth together
[137,167,183].
4.11. Complications
Side effects of cosmetic BoNT are usually mild and transient. The most common side effects
are pain, swelling, bruising and ecchymosis. Some transient rare systemic side effects such
as weakness, fatigue, nausea, pruritus and flu-like syndromes have also been reported [184].
These symptoms are usually transient and there is no need for any treatment. It is important
to use the smallest needle possible to minimize the bruising. Injection into the superficial
vessels, should also be avoided and the toxin should be injected into the subcutaneous layer.
Bruising usually resolves in 10 days [136]. The headache usually occurs on the first day after
injection, and it is not due to BoNT. The studies have shown that it is related to the injection
procedure itself [185]. Injecting the lower half of the frontalis muscle can cause brow ptosis.
This also can occur by diffusion of the BoNT into the lower half of the frontalis muscle. For
the patients with pre-existing brow ptosis, the frontalis injections should be avoided. It has
been suggested that the higher the volume, the greater the diffusion [186]. Transient upper
eyelid ptosis may occur in the first two days after glabellar BoNT injections. This is due to
toxin diffusion through the orbital septum, to the upper eyelid levator muscle. This condi‐
tion usually resolves itself over the first week [184]. This can be prevented by using high
dose, low volume BoNT no closer than 1 cm above the orbital rim. It has been seen that Dys‐
port diffuses more than Botox. It is also important to apply digital pressure on the orbital
rim during injection to prevent the toxin diffusion. Ectropion has seen in patients with pre-
existing lower eyelid laxity, due to weakening the orbicularis oculi muscle with BoNT [187].
When treating crow’s feet, the inferior limit for injection should be superior to the zygomatic
arch and the injections should not be deep, because this can cause zygomaticus major palsy,
which is responsible for the lip drop after BoNT injection [181]. It has been suggested that
the patient could exhibit an allergic reaction to the albumin that is used in the preparation of
some BoNT products. The estimated lethal dose of BoNT-A for humans has been estimated
about 2500 to 3000 U, which shows that it has a large margin of safety [106].
5. Facial resurfacing
Facial resurfacing refers to procedures that change the texture and appearance of skin. Photo-
aging and acne scarring are the most common reasons for which patients seek resurfacing pro‐
cedures. Facial resurfacing includes mechanical derm-abrasion in 1905 by Kromayer, the Baker-
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Gordon phenol peel in the 1960s, the laser principle of selective photo-thermolysis by Anderson
and Parrish in 1983, and medium-depth chemical peeling by Brody in 1986 [188-191].
5.1. Anatomy of the skin
The skin consists of two layers: the epidermis and the dermis. The epidermis is composed of
epithelium which is subdivided into 5 layers: the stratum corneum, stratum lucidum, stra‐
tum granulosum, stratum spinosum, and the stratum basale. The stratum corneum is the
most superficial layer and composed of layers of keratinocyte. The stratum lucidum con‐
tains a dense layer of keratin filaments that provides additional structural support. The stra‐
tum granulosum contains lipid granules which makes the skin waterproof. The stratum
spinosum is characterized by the presence of multiple spiny cells containing cytokeratin.
The stratum basale generates the cells composing all other layers of the epidermis. The der‐
mis consists of two layers: the papillary layer and the reticular layer. The papillary layer
contains the capillary network and nerve endings. The reticular layer contains densely
packed collagen, hair follicles and sweat and sebaceous glands [192].
5.2. Patient selection
The ideal patient for a resurfacing procedure is one who has signs of photo-aging or acne
scarring. Acne scarring is classified as ice pick, rolling, or boxcar type. Ablative resurfacing
is most effective for boxcar and rolling types [193].The first step is to review the patient’s
medical history and lifestyle. Patients with a history of keloids, smoking, extensive under‐
mining of skin and facelift surgery in the last 6 months, history of skin radiation, HSV infec‐
tions and diabetes are relative contra-indications to ablative procedures [194]. Chronic
smoking causes micro-vascular damage and leads to poor tissue healing. Smoking should be
stopped as least a month prior to peeling and 6 months after that [195].Excessive sun expo‐
sure could also lead to poor healing and the patient should be advised to avoid sun expo‐
sure after peeling [195]. Birth control pills, exogenous estrogens and photosensitizing drugs
are to be avoided because of risks of hyperpigmentation. The patients who are planning to
become pregnant within the first 6 months after treatment are not good candidates for peel‐
ing due to the elevation of the estrogen level. [196]. Isotretinoin use is an absolute contrain‐
dication to resurfacing procedures, because it prevents re-epithelialization and should be
stopped 12 to 24 months prior to the treatment [195].
5.3. Pretreatment skin preparation
Skin preparation and protection is essential prior to resurfacing treatments. These pretreat‐
ment considerations contain preconditioning the skin with topical retinoids, alpha-hydroxy
acids, and hydroquinones and photo-protection after ablative procedures [197]. Sunscreens
should be started to prevent pre-peel burns or tanning to decrease melanocyte activity 3
months prior to the peel in combination with minimal sun exposure [195]. Tretinoin aids in
re-epithelialization and leads to increased melanin distribution [198]. It also has synergistic
qualities with trichloroacetic acid [199,200]. It is recommended to use topical tretinoin
(0.05% to 0.1%) 6 to 12 weeks prior to the treatment.
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Hydroquinone is used prior to treatment in patients with melisma, dyschromia, lentigines,
hyper-pigmentation and Fitzpatrick skin types 3 to 6 [201]. Hydroquinone decreases mela‐
nin production by blocking tyrosinase and preventing the conversion of tyrosine to L-Dopa.
Hydroquinone (4 to 8%) should be started 4 to 6 weeks prior to treatment. Antiviral prophy‐
laxis should be started prior to the procedure. Acyclovir should be used 400 mg 3 times a
day, or 500 mg twice a day, 3 days prior to the treatment and should be continued for at
least 7 days after. For those patients with a positive history of active HSV infections, Valacy‐
clovir 1 g should be used [202,203]. A study by Manuskiatti et al. showed a bacterial infec‐
tion rate of 4% in patients pretreated with prophylactic antibiotic undergoing laser
resurfacing and 8% in the untreated group [204,205]. The use of appropriate prophylactic
antibiotic especially against staphylococcal and streptococcal species is recommended, but it
is controversial.
It is necessary for the patient to avoid waxing, derm-abrasion, and electrolysis for 3 to 4
weeks prior to peeling. These procedures could affect the uniform depth penetration of the
peeling agents [195].
5.4. Resurfacing procedures
Resurfacing  procedures  are  classified  into  ablative  or  non-ablative  procedures.  Ablative
procedures are those which wound the skin to the level of the dermis. These procedures
include chemical peels,  derm-abrasion, laser ablation and plasma resurfacing techniques.
They can cause a wound to the level of superficial, medium or deep. The disadvantages
of  these  techniques  are  increased  risk  of  infection,  erythema,  post-inflammatory  hyper‐
pigmentation,  cicatrical  scarring  and  hypopigmentation.The  non-ablative  procedures  in‐
clude lasers and radiofrequency techniques. Their advantages are minimal recovery time
and low risk of scarring.
5.4.1. Chemical peel resurfacing
5.4.1.1. Introduction
Chemical resurfacing is the application of chemical agents to produce a controlled partial
thickness wound of the skin. Chemical peeling agents are categorized as superficial, medi‐
um, and deep based on the depth of ablation. Superficial peels cause exfoliation of the epi‐
dermis, medium peels cause epidermal to papillary dermal peel and deep peels penetrate to
the reticular dermis [202,206].
5.4.1.2. Indications
Chemical peel indications are rhytides, irregular pigmentation, scars, actinic keratosis, and
acne [207]. Superficial peels are effective for treating the mild actinic damage, superficial
lentigines, mild rhytids, post-inflammatory erythema and mild photo-aging. The superficial
peels result in epidermal sloughing and mild inflammatory response in the superficial papil‐
lary dermis. They are safely used in all Fitzpatrick skin types. Medium depth peels are used
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for dyschromia from dermal melasma moderate photo-aging and mild to moderate acne
scars. They result in sloughing of the epidermis, variable necrosis of the papillary dermis
and some inflammation within the reticular dermis. These peels should not be used for Fitz‐
patrick skin type 5 and 6, due to the risk of dyschromia [208]. Deep peels are used for ad‐
vanced photo-aging and deep rhytids of the perioral and peri-orbital. They create sloughing
of the epidermis and papillary dermis and cause inflammation within the reticular dermis.
They should be used for patients with Fitzpatrick skin type 1 and 2 [195].
5.4.1.3. Superficial chemical peels
Alpha-hydroxy acids (AHAs) are usually used for superficial peeling. They include glycolic
acid and lactic acid. They are time-dependent and after achieving appropriate peeling
depth, they should be neutralized by using ammonium salts, sodium bicarbonate or sodium
hydroxide to prevent excessive peeling and healing problems [201,206]. These agents affect
epidermis and the superficial dermis by creating the loss of cohesion of keratinocytes.Sali‐
cylic acid is a beta-hydroxy acid agent which exfoliates the dead skin cells. This agent is usu‐
ally used in combination with other agents [209]. Jessner’s solution consists of 14 g salicylic
acid, 14 g lactic acid, 14 g resorcinol in 100 ml of 95% ethanol [202,203]. Its penetration depth
is coat-dependent. By applying one to three coats the penetrations depth is limited to the
stratum corneum. However, by applying 5 to 10 coats, the penetration depth extends to the
basal cell layer.The desired end point of superficial agents can be determined by erythema
and light peeling of the epidermis. A clear frost indicates penetration into the dermis and
should be avoided [210,211]. Mild stinging occurs during the procedure which resolves
within a few minutes. Mild erythema subsides within a few hours. Desquamation begins 2
to 3 days later and can last 1 to 4 days. Usually 3 to 5 treatment sessions spaced 2 to 4 weeks
apart are necessary for desirable results.
5.4.1.4. Medium-depth peels
Trichloroacetic acid (TCA) is the gold standard agent used for medium-depth peeling. At
concentrations up to 35%, it acts as a medium depth peel, but at concentrations of 45% to
50%, acts as a deep peel [212]. The risk of scarring increases at concentrations more than 50%
[213]. It does not require neutralization. To lessen the risk of scarring, and to achieve the ap‐
propriate peeling depth, Coleman combined glycolic acid with 35% TCA [214].When com‐
bining Jessner’s or 70% glycolic acid with 35% TCA, Jessner’s solution or glycolic acid is
applied first within 60 seconds until a faint frosting with mild erythema appears. The glycol‐
ic acid needs to be neutralized [215]. Jessner’s solution is allowed to dry. Then the 35% TCA
is applied [216]. Jessner’s solution destroys the epidermis and allows for even application of
the TCA solution to achieve a deeper penetration [217].The endpoint is a white frost that
usually appears within 30 to 120 seconds of application. If it does not appear, additional
passes are done. It is important to wait at least 120 seconds between passes for the frost to
appear. The face develops erythema for the first 12 hours, followed by moderate edema. Full
re-epithelialization usually occurs 7 to 10 days after the treatment. The treatment can be re‐
peated as necessary on a yearly basis.
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5.4.1.5. Deep phenol peels
The Baker-Gordon solution is usually used for deep peels. It consists of 3ml of 88% phe‐
nol, 3 drops of 2.1% Croton oil, 8 drops of Septisol and 2ml of water [218,219]. This mix‐
ture  should  be  freshly  prepared  for  each  treatment.  It  was  thought  that,  phenol  was
responsible for deep peeling,  but Hetter  showed that  in fact,  croton oil  was responsible
for peeling [220]. Because the potential toxic effects of phenol to the cardiac system, and
its  ability for causing cardiac arrhythmias,  the blood pressure,  pulse oximetry and ECG
monitoring should be  used during treatment.  This  complication is  more common when
more than half  of  the face is  treated in less than 30 minutes [207,221].  It  also can cause
renal  toxicity  and  irreversible  hypopigmentation  and  should  be  used  only  in  patients
with Fitzpatrick skin type 1 and 2 [195].  The deep phenol peel is applied within 15 mi‐
nutes interval between each esthetic unit. The endpoint of the application is a white frost
followed by a deep brawny erythema. The skin should be protected and moistened dur‐
ing the first  4  days after  the treatment  [218].  Full  re-epithelialization occurs  in  10 to  14
days. The erythema typically resolves within 2 months [194].
5.4.1.6. Technique
Prior to application of peeling agent, preparing the skin is needed. A soap free cleanser is
used to remove makeups. Then the skin is vigorously cleaned by rubbing alcohol or acetone
for about 3 minutes to degrease the skin and reach a brisk erythema [195]. 10 to 15 mg oral
diazepam is usually administered preoperatively to reduce the patient’s anxiety. The intra‐
venous catheter is placed and fluid therapy is administered for the patient to regain intra‐
vascular volume. Usually a sedative dose of propofol is administered. Then the supra-
orbital, infra-orbital and mental nerves are blocked by lidocaine 2% without epinephrine, to
prevent the accumulation of the phenol agent. The peeling agent is uniformly applied to
each esthetic unit (forehead, left cheek, right cheek, nose, chin, and peri-orbital area) with a
cotton gauze. The cotton tipped applicator is used for the application of phenol peels. The
upper eyelids should be left untreated. The peel should be performed to within 3 mm of the
cilliary line of the lower eyelids [194,195]. If phenol is used, 10 to 15 minutes must be al‐
lowed between each unit peeled for the phenol clearance. The peel should be carried into
the hairline and over the vermillion border to prevent lines of demarcation. The adjacent es‐
thetic units should also be peeled adequately by overlapping the adjacent application areas
for the same reason.
5.4.1.7. Post-operative care
The burning sense may last up to 8 hours after the treatment. An oral narcotic analgesic is
usually prescribed to minimize the burning sensation. When the frost subsides and only er‐
ythema persists, a bland emollient should be applied to the skin to ease the skin monitoring
on a daily basis. A day after treatment, the patient is advised to apply cream, 3 times a
day.In the first 12 weeks after the treatment, sun exposure can result in hyperpigmentation
and the patient should be advised to avoid excessive sun exposure. The sunscreens should
also be avoided for the first 6 weeks because of their para-amino-benzoic acid formulation
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which could lead to irritation and erythema [195].The healing process occurs in five stages.
The first stage is inflammation which increases during the first 12 hours. At the second
stage, the epidermis becomes leathery and separates from the dermis and sloughs. The third
stage is desquamation and will occur over 4 to 7 days. At the fourth stage, re-epithelializa‐
tion begins within 48 to 72 hours and lasts about 7 to 10 days. Finally, fibroplasia begins
within the first week and continues for 3 to 4 months after the treatment [222].
5.4.1.8. Complications
As mentioned earlier, cardiac arrhythmias is one of the complications of the phenol peels.
When it happens, the patient will develop a supraventricular tachycardia within 30 minutes,
which if continues can lead to ventricular tachycardia and atrial fibrillations. Once arrhyth‐
mia is noted, the treatment should be stopped and adequate fluid therapy should be admin‐
istered until the patient’s rhythm is back to normal [195]. If re-epithelialization does not
occur within 10 days after the treatment, those areas should be checked for the presence of
infection [223]. Bacterial infection can delay wound healing and lead to scarring. In this case
antibacterial therapy should be initiated. HSV infection can also occur and must be treated
with 1g Valacyclovir, 3 times a day for 10 days [195].The erythema may last longer than ex‐
pected in patients with sensitive skin. The administration of topical 2.5% hydrocortisone lo‐
tions are recommended in these patients [195]. Post-inflammatory hyperpigmentation might
occur in patients with Fitzpatrick skin type 3 to 6. For eliminating this, the use of glycolic
acid lotion or the combination of 0.05% retinoic acid, 8% hydroquinone and hydrocortisone
cream is recommended [224]. Hypopigmentation may occur by using phenol peels and this
complication is irreversible.
5.4.2. Dermabrasion
5.4.2.1. Introduction
Derm-abrasion is a skin-resurfacing technique that has been around since the 1930s. It has
been used for treating wrinkles, scars, and the precancerous lesions [195,225]. By performing
the derm-abrasion, the epidermis and partial of the underlying dermis is mechanically re‐
moved. Usually two passes are performed, in directions perpendicular to each other. Kro‐
meyer was the first performed derm-abrasion using a rotating burr or rasp after freezing the
skin with carbon dioxide snow or ether spray [189]. Derm-abrasion is ideally performed in
the face because of its high density of skin appendages. The neck has thinner dermis and
less skin appendages and should be avoided because of the risk of hypertrophic scarring
and depigmentation occurrence [195].
5.4.2.2. Indications and contra-indications
Its indications are similar to superficial chemical peels including boxcar and rolling acne
scars, rhinophyma, scarring, tattoos, lentigines, facial rhytides, fine perioral rhytids, sebor‐
rheic or actinic keratosis and removal of benign and premalignant epidermal growths. Indi‐
cations for full thickness derm-abrasion include deep peri-orbital or perioral rhytids [226]. It
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is also used to revise scars from trauma, skin grafts, and surgical incisions [225].Treating hy‐
pertrophic scars and keloids with derm-abrasion is contra-indicated due to the lack of ad‐
nexal structures for epidermal regeneration. Use of isotretinoin within the recent year is also
contra-indicated, due to their healing impairment which leads to keloid formation [195].
Derm-abrasion during active acne is a relative contra-indication due to its increased risk of
postoperative infection [225].
5.4.2.3. Dermabraders and devices
Many dermabraders are available for skin resurfacing, which are connected to a pneumatic
or electric motor rotating handpiece. The desired speed for derm-abrasion is approximately
12,000 to 15,000 revolutions per minute. The most common dermabraders include diamond
burs, serrated wheels, or wire brushes [194]. During the procedure, they must be kept in
contact with the skin with a gentle pressure [225]. One of the alternative equipments that is
useful for derm-abrasion of the scars is sterile, medium grade (220 grit) silicone carbide
sandpaper that is wrapped around gauze [227].
5.4.2.4. Pre-operative considerations
Any patient with the history of isotretinoin use during the past year is prone to hypertro‐
phic scarring or keloid formation due to their delayed wound healing and should not under‐
go the procedure. Those patients who use blood-thinners and having bleeding disorders are
prone to post-operative hyperpigmentation and if medically possible, their medication
should be discontinued. Patients with the history of HSV may require prophylactic antiviral
medications [225]. Patients with darker skin shades are more prone to irreversible hypopig‐
mentation and are not good candidates for derm-abrasion [225]. Administration of tretinoin,
a few weeks before the procedure is recommended due to its promotion of the wound heal‐
ing process.
5.4.2.5. Pre-operative considerations
Derm-abrasion is usually performed under local anesthesia, but sedation or general anes‐
thesia could also be used due to the patient’s pain tolerance and patient’s overall health
[225].  The patient’s ECG, blood pressure and pulse oximetry should be monitored if  se‐
dation or general  anesthesia is  used. Regional nerve blocks are administered adequately
before the procedure [194]. The appropriate diamond bur or wire brush is chosen and at‐
tached to the handpiece.  Diamond burs abrade the skin slowly and are more conserva‐
tive than wire brushes and serrated wheels [195]. The affected area is stabilized with the
non-dominant hand, and the handpiece is held at a right angle to the skin with the dom‐
inant  hand  and  by  applying  slow  and  even  pressure  to  the  skin,  the  dermabrader  is
moved across the skin in a back and forth motion for diamond burs and in one-direction
motion for  wire  brushes  [228].When performing the derm-abrasion,  the  epidermal  layer
is  removed first.  Then by  entering  the  papillary  dermis,  pinpoint  bleedings  from small
capillary loops occur. By the disappearance of the pinpoint bleedings, the upper reticular
dermis  has  been  reached  and  small  parallel  strands  of  whitish-yellow  colored  collagen
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are  visualized.  The  papillary-reticular  junction  is  the  ideal  endpoint  of  derm-abrasion
and is identified by increased, confluent bleeding. No more penetration into the reticular
dermis should be performed, due to the risk of scar formation [194,195,225]. The periph‐
ery of the area should be slightly feathered to blend treated and untreated areas. Protec‐
tion  from  blood  exposure  and  aerosolized  particles  must  be  considered  during  the
treatment, especially for patients with a history of HIV or hepatitis.
5.4.2.6. Post-operative care
Immediately following the procedure, saline-soaked gauze moistened with dilute epinephr‐
ine is placed on the wounds to achieve hemostasis [225]. Post-operatively, the wound is
cleansed daily with a wet gauze and petroleum-based products are applied several times a
day to moistens the wound and keep it from crusting. Re-epithelialization time is approxi‐
mately 5 to 7 days and is fully completed by day 10 to 14 [225]. Erythema is common and
can persist for 2 to 3 months [195]. Patients should avoid excessive sun exposure for 6 to 12
months following the procedure to avoid hyperpigmentation. Hydroquinone can be used to
treat post-inflammatory hyperpigmentation following the procedure.
5.4.2.7. Complications
Common complications  include  dyspigmentation,  hypertrophic  scarring,  acne  eruptions,
and postoperative infections [195].  If  the derm-abrasion is  performed beyond the reticu‐
lar dermal layer, it can lead to abnormal scarring, hypertrophic scars and keloids. It is al‐
so  seen  in  patients  with  collagen  disorders.  Excessive  sun  exposure  can  lead  to  post-
inflammatory  hyperpigmentation  and  hydroquinone  is  administered  to  treat  this
condition [225]. Patients with Fitzpatrick skin types 3 to 6 are prone to irreversible hypo‐
pigmentation. Patients with active acne are more prone to infection. Infections should be
treated  with  antibiotic  and antiviral  therapy.  Patients  with  a  history  of  HSV should  be
treated with prophylactic antivirals. The formation of Milia is a small white keratin-filled
cyst,  which might occur following derm-abrasion. Its treatment is incision and drainage,
if it does not resolve spontaneously [225].
5.4.3. Microdermabrasion
Microdermabrasion is a less invasive and less painful skin resurfacing technique that uses
an inert substance such as aluminum oxide or sodium chloride crystals to remove the super‐
ficial layers of the skin. It is used for the treatment of photo-damaged skin, hyperpigmenta‐
tion, superficial rhytides, stretch marks, scars, acne scarring, and enlarged pores [225,229]. It
can be performed on all Fitzpatrick skin types. The operator uses a device that mobilizes a
fine stream of ablative substances on the skin with the intent of disrupting the stratum cor‐
neum. The cells at the most superficial layer are dislodged and simultaneously removed by
vacuum suction [225].Side effects include mild erythema and tenderness. These complica‐
tions are treated with non-steroidal anti-inflammatory drugs.
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5.4.4. Laser resurfacing
5.4.4.1. Introduction
Lasers are generally categorized into 2 groups: ablative and non-ablative lasers. Ablative la‐
sers are mostly used for the treatment of photo-damaged skins, deep rhytides, solar elastoses,
uncontrollable acne, acne scars, telangectasias and actinic keratosis. These lasers ablate the
outer layers of the skin to the level of the dermis and cause thermal damage to the dermis re‐
sulting in collagen remodeling and new collagen formation which leads to smoother and firm‐
er skin [195,230,231]. Patients with Fitzpatrick skin type 1 to 4 are good candidates for ablative
laser resurfacing [232]. Non-ablative laser are less aggressive and cause minimal injury to the
epidermis and their side effects are less than ablative lasers. They are effective in the treatment
of mild to severe rhytides [195,230]. Fractional photo-thermolysis (FP) is a laser technology
with decreased side effects and improved recovery time. FP therapy is done by delivering an
ablative or non-ablative laser to the skin to create micro-thermal zones of injury. By this meth‐
od the normal skin is preserved and treated area is decreased which leads to improved recov‐
ery time [195,233]. The surrounding unaffected follicular units and fibroblasts are responsible
for rapid collagen remodeling and faster recovery time. FP is effective in the treatment of
moderate to severe acne scarring and moderate to severe photo-aging [234].
5.4.4.2. Ablative lasers
Ablative lasers include the CO2 and Er:YAG devices. They cause homogenous tissue vapori‐zation with surrounding residual thermal damage after selective absorption by intracellular
water in the epidermis. Er:YAG lasers have 10 times more absorption by water than CO2 lasersand  are  able  to  ablate  the  tissue  more  precisely  with  less  residual  thermal  damage
[235,236].The CO2 laser was first introduced in the 1980s and initially it created excessive ther‐mal damage and lead to excessive scar formation [195]. CO2 laser works by delivering energyat 10,600 nm wavelength. For decreasing the residual thermal damage, the CO2 in delivered at5 J/cm2 in less than 1 millisecond, which creates 20 to 30 μm of tissue ablation and 40 to 120 μm
of residual thermal damage [194]. CO2 lasers are able to ablate tissue of the reticular dermis,because of their hemostatic effects.The Er:YAG laser is an alternative for CO2 with minimizedrisks. The laser beam is delivered at 2940 nm wavelength, which is close to the peak absorp‐
tion of water at 3000 nm. This would limit the penetration depth and residual thermal damage
and leads to less side effects and decreased healing time [195]. The energy is delivered at 0.6 to
5 J/cm2 which causes 4 μm of tissue ablation and 10 to 40 μm of residual thermal damage. The
ablation depth of Er:YAG lasers are limited to the papillary dermis due to their inability to co‐
agulate blood vessels. Bleeding absorbs the laser light and prevents further penetration. Usu‐
ally these two lasers are combined to minimize the side effects and maximize the benefits.
After the treatment with CO2 laser, Er:YAG is used to remove the coagulated tissues producedby the CO2 laser, which leads to shorter healing time [195].
5.4.4.3. Non-ablative lasers
Non-ablative lasers are introduced to minimize the tissue damage and healing time. These
lasers are divided into three groups: infrared lasers, intense pulsed light (IPL) and visible
lasers. Infrared lasers which are mostly used include the 1320 nm Nd:YAG laser, 1450 nm
A Textbook of Advanced Oral and Maxillofacial Surgery794
diode and 1540 nm erbium-doped phosphate glass laser. These lasers only target the dermis
to promote new collagen formation and rhytides improvement, and are not effective on pa‐
tients with epidermal changes and severe photo-damaged skin [195].IPL devices are not real
lasers, but they have a wide spectrum range 550 to 1200 nm. They are able to target the he‐
moglobin, melanin and blood vessels, so they are used for the treatment of dyschromias, te‐
langiectasias, increased vascularity and pigment changes from photo-damaged skin [195].
Visible lasers include pulsed dye laser (PDL) and pulsed 532 nm potassium titanyl phos‐
phate laser (KTP). These lasers target the blood vessels and superficial pigmentations and
are used to treat telangiectasias in photo-damaged skins [195].Lasers have been combined
with radiofrequency (RF) devices to increase the depth of the lasers penetration without in‐
creasing the ablative effects. This increased penetration depth leads to increased skin tight‐
ening and increased new collagen formation [230,237].
5.4.4.4. Indications
The indications for CO2 and Er:YAG lasers include acne scarring and moderate to severe
photo-aging. CO2 laser is also used for the treatment of the skin laxity and deep rhytides
[238,239].
5.4.4.5. Technique
Each esthetic unit is treated individually. The borders of the units should be feathered to pre‐
vent demarcation lines. Overlapping of the pulses is not recommended with CO2 resurfacing
[240]. Lasers could cause damage to the hair follicles, therefore protecting the hair is mandato‐
ry.The endpoint of the treatment is a visible smoothing of the rhytids. This is achieved by 1 to 4
passes with CO2 laser. Between the passes, the epidermal debris should be wiped away. When
using Er:YAG laser, because of its minimal residual thermal damage, the overlapping of the
pulses is possible and wiping the debris between the passes is not necessary [241].
5.4.4.6. Post-operative care
The postoperative care is similar to that described for deep phenol peels. The full re-epitheliali‐
zation time with laser resurfacing is approximately 7 to 10 days which is faster than with deep
phenol peeling. Usually the erythema, edema and crusting occur during the first 3 to 4 days.
5.4.4.7. Complications
The erythema usually lasts from 1 to 4 months and may even last up to a year. The post-
inflammatory hyperpigmentation is common in patients with Fitzpatrick skin type 3 to 6.
Hydroquinone and retinoic acid may be used to treat this hyperpigmentation and the pa‐
tients should be advised to avoid excessive sun exposure. Hypopigmentation may occur 6 to
12 months after the treatment which is irreversible. In the case of infection, antimicrobial
agents should be used for treatment. Acne eruptions are common in patients with a history
of acne and should be treated with standard acne treatments. The risk for scarring is higher
with CO2 resurfacing compared with erbium resurfacing because of the higher residual ther‐mal damage.
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5.4.5. Fractional photo-thermolysis (FP)
The traditional ablative and non-ablative lasers create a homogenous zone of thermal dam‐
age, but FP creates multiple microsomal thermal zones surrounded by normal skin with in‐
tact stratum corneum, which results in a shorter healing time [242]. Each microsomal
thermal zone consists of an area within 70 to 100 μm wide and 250 to 800 μm deep contain‐
ing necrotic debris of epidermal and dermal tissues [243]. Ablative FP devices include CO2,
Er:YAG and yttrium scandium gallium garnet and they have high affinity for water mole‐
cules. Non-ablative FP devices include 1550 nm erbium doped laser, 1540 nm pulsed device,
1440 nm neodymium yttrium aluminum garnet and 1410 nm erbium fiber devices. These
devices have moderate affinity for water.
 
A B
Figure 5. A patient treated with fat and PRP injection. A, Before treatment. B, After treatment.
 
A B
Figure 6. A patient treated with fat and PRP injection. A, Before treatment. B, After treatment.
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6. Conclusion
The field of cosmetic surgery continues to be a rapidly changing and expanding one. Use of
minimally invasive facial rejuvenation continues to increase. With the understanding of the
changes that take place in aging and contribute to photo-damaged skin, technologic advan‐
ces have become more science-based. Patients are aware of these changes and it has become
more important than ever for surgeons to be knowledgeable about available procedures,
limitations, techniques, risks and complications. Figures 5 and 6 show two patients before
and after treatment.
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